Document is current
Any future updates will be listed below
-
Authors
Wattiez, Anne-Sophie
Kuburas, Adisa
Castonguay, William C.
Fejgin, Kim
Klewe, Ib V.
Russo, Andrew F.
-
Funding
Funding for this research was provided by:
NIH (R01 NS075599)
Iowa City Veterans Affairs Medical Center (I01 RX003523-01)
H. Lundbeck A/S
- License Information
-
More Information
Article History
Received: 12 May 2025
Accepted: 29 June 2025
First Online: 4 August 2025
Declarations
:
: Ethical approval was obtained for experiments with CGRP and SNP from the University of Iowa Animal Care and Use Committee and carried out in accordance with the standards set by the US National Institutes of Health.
: AFR is a consultant and/or on advisory boards for Lundbeck, AbbVie, Pfizer, Vedana Pharmaceuticals, Arrowhead Pharmaceuticals, and Delphian Therapeutics, and holds patents on the CGRP monoclonal antibody for photophobia and diarrhea, on the PACAP monoclonal antibody for photophobia, and on the CGRP HO enhancer element. AK is a consultant for Vedana Pharmaceuticals. KF and IVK are employees of Lundbeck. A-SW and WCC declare no competing interests. Disclaimer: this work was performed while A-S Wattiez was employed at the University of Iowa. The opinions expressed in this article are the authors’ own and do not reflect the views of the National Institutes of Health, the Department of Health and Human Services, or the United States government.
